MCP conjugation of panitumumab enables higher SA labeling with 111In or 177Lu than DOTA-panitumumab (Aghevlian et al., 2018) which could theoretically deliver more activity to tumour cells per EGFR binding event, resulting in a higher absorbed dose, but in the current study panitumumab-DOTA-[111In]In and panitumumab-MCP-[111In]In were labeled at the same SA (1 MBq/μg; ~ 144 MBq/nmole). This evidence concerns the gene EGFR and neoplasm.